Abstract
What is this summary about?
This is a summary of the publication about the DESTINY-Lung01 study, which was published in the New England Journal of Medicine in September 2021. The DESTINY-Lung01 study includes 181 adults with metastatic non-small-cell lung cancer (NSCLC) that could not be treated with surgery and who have had previous standard anticancer treatment. The publication includes information and results about 91 of the 181 study participants. These 91 participants had HER2-mutant NSCLC. Researchers wanted to learn if the drug trastuzumab deruxtecan (T-DXd) could help treat participants with HER2-mutant NSCLC. At the time of this publication, this study is ongoing.
What are the key takeaways?
Results from the study showed that 55% of participants responded to treatment with T-DXd. The median length of time participants continued to respond to T-DXd was 9.3 months.
After receiving T-DXd, 92% of participants had disease control. After receiving T-DXd, half of the participants lived for at least 17.8 months. After receiving T-DXd, half of the participants lived for 8.2 months before their cancer got worse.
During the study, 97% of participants had drug-related adverse events, with nausea being the most common. There were 20% of participants with serious drug-related adverse events.
What were the main conclusions reported by the researchers?
Based on these results, T-DXd could be a treatment option for people with HER2-mutant NSCLC that has been previously treated.
Clinical Trial Registration: NCT03505710 (DESTINY-Lung01) (ClinicalTrials.gov)
Keywords: :
This is an abstract of the Plain Language Summary of Publication article.
To read the full Plain Language Summary of this article, click here to view the PDF.
Link to original article here
Financial disclosure
Dr. Smit reports research grants paid to his institution, Netherlands Cancer Institute by Novartis Pharma. Daiichi Sankyo Co., Ltd., and AstraZeneca funded this study. The study was designed and led by Daiichi Sankyo Co., Ltd., for data collection and analysis, and was approved by the institutional review board at each partnering site. In March 2019, AstraZeneca entered into a collaboration agreement with Daiichi Sankyo Co., Ltd., for trastuzumab deruxtecan (T-DXd). All authors and sponsors assisted in data interpretation, writing the report, and reviewing the manuscript, and provided final approval to submit the manuscript for publication. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Acknowledgments
Daiichi Sankyo and AstraZeneca would like to thank the clinical study participants and their family members and caregivers. They would also like to thank the staff members at the study centers who cared for the participants in the clinical study.
Competing interests disclosure
Dr. Smit has been a consultant for Eli Lilly and Company, and a speaker for AstraZeneca and Bristol Meyers Squibb Company. Dr. Smit has also served on a scientific advisory board for AstraZeneca, Bristol Myers Squibb Company, Daiichi Sankyo Company, Merck, Merck Sharp and Dohme, and Seagen Inc. The author has no other competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript apart from those disclosed.
Writing disclosure
Medical writing and editorial assistance in the development of this summary were provided by Kim Edwards, PhD, and Scott Finger of the Center for Information & Study on Clinical Research Participation (CISCRP), a non-profit organization focused on educating and informing the public about clinical research participation, and funded by Daiichi Sankyo.